BioAge reports phase 1 results for NLRP3 inhibitor BGE-102

April 21, 2026 7:01 AM

BioAge Labs, Inc. (NASDAQ: BIOA) reported results from a phase 1 clinical trial of BGE-102, an oral NLRP3 inhibitor, showing ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found